Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07374068
Active, not recruiting Observational

Prognostic Model of Elderly Hodgkin Lymphoma in China

NCT07374068 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Observational
Started
2025-12-09
Last updated
2026-01-28

Condition(s) studied

Hodgkin Lymphoma

Study summary

This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.

The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥60 years * Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma * Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy * Availability of complete clinical, pathological, and follow-up data Exclusion Criteria: * Presence of other malignant tumors * Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate \<30 mL/min) * Missing more than 20% of required clinical data

Primary outcome measure(s)

  • Overall Survival (OS) — From date of diagnosis until death from any cause, assessed up to 60 months.
    Overall survival (OS) is defined as the time from diagnosis to death from any cause.

Trial sites (1)

FacilityCityRegionStatus
Tianjin Cancer Hospital Tianjin Tianjin Municipality

More Tianjin Medical University Cancer Institute and Hospital trials in China

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure Recruiting
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer Recruiting
Real-world Studies of CDK4/6 Inhibitors Recruiting
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI Active, not recruiting
Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery Recruiting

Other trials for the same condition

The Pathogenesis and Prognostic Factors of Lymphoma Recruiting
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma Starting soon
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) Recruiting
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Active, not recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07374068 on ClinicalTrials.gov ↗ ← All trials in China